Hims and Hers Health Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Hims and Hers Health Inc trades at $29.06 (market cap $6.55B), while Vanguard Total International Stock Index Fund ETF trades at $84.52 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 101.6× Hims and Hers Health Inc's market cap, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| HIMS | VXUS | |
|---|---|---|
Market Cap | $6.55B | $665.70B |
Volume | 14,842,814 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $62.76 | $88.41 |
52-Week Low | $14.52 | $72.17 |
Typical Hold Time | 21 Days | 55 Days |
Enterprise Value | $7.25B | — |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
VXUS, the Vanguard Total International Stock ETF, trades at $84.56, down 0.26% with a bearish technical signal. The ETF provides diversified exposure to international developed and emerging markets outside the US. Recent news highlights its role in portfolio diversification and institutional buying interest, though technical indicators show selling pressure across moving averages and oscillators.
The outlook for VXUS hinges on international market performance relative to US equities, with potential for long-term growth diversification. Risks include currency fluctuations and regional economic volatility. Institutional accumulation suggests confidence in international equity exposure as a strategic portfolio component.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →